Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

SARS-CoV-2 Drug Discovery and Vaccine Development

Through innovation and collaboration, the scientific community rapidly came together to discover and develop numerous SARS-CoV-2 therapeutics and vaccines; however, the search for effective therapeutics and vaccines continues. The viral life cycle provides many areas that new drugs can target, from virus:host interaction to viral protease activity. Evolving SARS-CoV-2 variants require therapeutics and vaccines to adapt.

Promega offers several assays and technologies to enable SARS-CoV-2 drug discovery and vaccine development. These assays and technologies include monitoring viral entry, detecting neutralizing antibodies and their ADCC or ADCP activity, and measuring viral protease activity.

Interested in more information about SARS-CoV-2 drug discovery and vaccine development?
We can customize a virtual presentation to answer your questions.

Request a Seminar

SARS-CoV-2 is a member of the coronavirus family. This retrovirus binds to the ACE2 host cell receptor through the viral surface Spike protein. The virus and its life cycle provide numerous opportunities for targeted drug discovery:

  • Inhibiting the 3CLPro and PLPro viral proteases, which are necessary for the viral life cycle
  • Preventing the binding of the viral Spike protein to the ACE2 host cell surface receptor, thereby preventing viral entry
  • Modulating the effects of the hyperactivated immune system caused by SARS-CoV-2 infection, like inflammation and cytokine release

As with therapeutics, many vaccines in development target the host antibody response against the SARS-CoV-2 Spike protein, to prevent viral entry into host cells.

SARS-CoV-2 structure

Learn more about products and technologies for viral research.

Virus:Host Interaction

SARS-CoV-2 enters mammalian cells through binding of its Spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor. Therapeutics that inhibit this interaction can prevent viral entry. The Lumit™ SARS-CoV-2 Spike RBD:hACE2 Immunossay measures the interaction between SARS-CoV-2 Spike protein receptor-binding domain (RBD) and human ACE2.

Lumit Spike RBD:hACE2 Immunoassay

Lumit™ SARS-CoV 2 Spike RBD: hACE2 Immunoassay principle. Detection of RBD-rabbit Fc:hACE2-mouse Fc interaction is performed by Lumit™ secondary antibodies (Lumit™ Anti-Mouse Ab-LgBiT and Lumit™ Anti-Rabbit Ab-SmBiT). Panel A. Binding of the antibodies to the proteins promotes the reconstitution of NanoLuc® luciferase, generating bioluminescence. Panel B. The presence of a molecule that disrupts the RBD-hACE2 interaction reduces the bioluminescent signal.


Protocol Summary

  1. Mix 25µl 3nM RBD + 3nM ACE2 proteins + anti-SARS-CoV-2 S1 antibody titration.
  2. Add 25µl Lumit™ antibody mix.
  3. Incubate 60 minutes at room temperature.
  4. Add 12.5µl Lumit™ detection reagent.
  5. Incubate 40 minutes at room temperature 
  6. Read luminescence.
Lumit™ Immunoassay Detects Specific Neutralizing Antibodies of the RBD:ACE2 Interaction

Anti SARS-CoV-2 antibody screening using the Lumit™ SARS-CoV-2 Spike RBD:ACE2 Immunoassay detects neutralizing antibodies (Nabs) with different inhibitory profiles. Monoclonal antibodies were serially diluted and incubated with SARS-CoV-2 Spike RBD-rabbit Fc for 30 minutes prior to the addition of hACE2-mouse Fc and Lumit™ antibodies.

This webinar recording (52min.) provides a detailed explanation of how the assay works and shows how it is used to screen for inhibitors of Spike RBD:ACE2 interactions.

Major SARS-CoV-2 RBD mutant variants are also available for use in this assay to explore the influence of RBD mutations on antibody binding.

Contact us for more information on the Lumit™ SARS-CoV-2 Spike RBD:ACE2 Immunoassay, or visit the product page.

Viral Entry

The SARS-CoV-2 HiBiT-PsVLP Assay was developed to measure the activity of small molecule inhibitors and neutralizing antibodies that block viral entry into the host cell. The assay uses innovative HiBiT bioluminescence technology to tag pseudotyped virus-like particles (PsVLPs) that contain the Spike protein on their surface. The PsVLPs are noninfectious because they contain no viral genetic material. 

Assay Design

  1. HiBiT-tagged VLPs pseudotyped with SARS-CoV-2 Spike protein are added to SARS-CoV-2 Target Cells. HiBiT is packaged inside the PsVLPs
  2. In the absence of inhibitors or neutralizing antibodies (nAbs), SARS-CoV-2 HiBiT-PsVLPs bind to target cells via Spike/ACE2 interaction and undergo membrane fusion mediated by cellular proteases. HiBiT is released into target cells and binds to LgBiT to generate a luminescent signal in the presence of substrate. 
  3. In the presence of inhibitors or nAbs against SARS-CoV-2 entry, the entry/fusion processes of PsVLPs are blocked, thereby preventing HiBiT release. No luminescent signal is produced. 
SARS-CoV-2 HiBiT-PsVLP Viral Entry Assay Design

Assay Workflow

This real-time assay is simple to use and can be completed in 3 hours. Advantages of this workflow include:

  1. Increased biosafety: HiBiT-PsVLPs are non-replicating, because no viral genome is present.
  2. Simple and rapid: No gene expression steps are required for assay readout. Monitor viral entry in live cells in real time.
  3. PsVLPs and Target Cells offered in Thaw-and-Use format: No need to generate live virus or pseudovirus, or to culture cells
  4. Quantitative assay readout
SARS-CoV-2 HiBiT-PsVLP Assay Workflow

SARS-CoV-2 HiBiT-PsVLPs
VSV-G HiBiT-PsVLPs

HiBiT-PsVLP entry is inhibited by neutralizing antibodies. SARS-CoV-2 HiBiT-PsVLPs (left) or VSV-G HiBiT-PsVLPs (right) were pretreated (30 minutes) with anti-Spike (Sino Biological #40592-R001) or anti-VSV-G (clone 8G5F11) neutralizing antibodies, respectively, and overlaid onto SARS-CoV-2 Target Cells. HiBiT-PsVLP entry was determined using the NanoGlo® Live Cell Assay System

SARS-CoV-2 HiBiT-PsVLP Entry
SARS-CoV-2 HiBiT-PsVLP Entry

SARS-CoV-2 HiBiT-PsVLP entry can be monitored in real time. SARS-CoV-2 Target Cells were treated with SARS-CoV-2 HiBiT-PsVLPs or assay buffer-only (Mock) (left). SARS-CoV-2 HiBiT-PsVLPs were pretreated (30 minutes) with Spike neutralizing antibody and overlaid onto SARS-CoV-2 Target Cells (right). HiBiT-PsVLP entry was monitored in real time using the Nano-Glo® Vivazine™ Live Cell Reagent.

Contact us for more information on the SARS-CoV-2 HiBiT-PsVLP Assay.

SARS-CoV-2 Antibody Detection

The Lumit™ Dx SARS-CoV-2 Immunoassay detects human antibodies against the receptor-binding domain (RBD) antigen within the S1 subunit of the SARS-CoV-2 Spike protein.

Visit the Lumit™ Dx SARS-CoV-2 Immunoassay product page for more information.

ADCC/ADCP Activity

The binding of SARS-CoV-2 Spike protein to the ACE2 receptor is a critical step for viral entry;  thus, the Spike protein is a main target for antiviral drug discovery and vaccine development. Besides neutralization by blocking Spike:ACE2 interactions, anti-Spike antibodies may have additional antiviral activities mediated by the antibody Fc domain. These activities include antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

ADCC Reporter Assay

The FcγR Reporter Bioassay uses engineered reporter effector cells and engineered target cells stably expressing the SARS-CoV-2 Spike (S) protein: 

  1. Anti-S antibody simultaneously binds to S protein on the target cells and the FcγRIIIa receptor on the ADCC Bioassay Effector Cells 
  2. This binding leads to the activation of FcγRIIIa receptor and activation of luciferase expression in the ADCC Bioassay Effector Cells. 
SARS-CoV-2 ADCC Reporter Assay Strategy
Measure ADCC Activity from Anti-SARS-CoV-2 S Protein (S2)
Measure ADCC Activity from Anti-SARS-CoV-2 S Protein (S2)

Measurement of ADCC reporter activity from Anti-SARS-CoV-2 S2 antibody. ADCC Bioassay Effector cells were incubated with SARS-CoV-2 S CHO-K1 target cells and anti-SARS-CoV-2 S2 antibody (Sino Biological, Cat.# 40590-D001) for 6 hours. Luminescence was measured using the Glo-Max® plate reader.

Contact us for more information on the SARS-CoV-2 ADCC Reporter Assay.


PBMC ADCC Reporter Assay

The PBMC ADCC Assay uses primary PBMCs and engineered target cells stably expressing SARS-CoV-2 Spike (S) protein and a HaloTag®-HiBiT protein. The assay takes advantage of HiBiT extracellular complementation technology:

  1. Anti-S antibody simultaneously binds to S protein on target cells and FcγRIIIa on primary NK effector cells.
  2. When ADCC occurs, lysis of the target cells releases HiBiT protein into the medium, which can be detected by NanoGlo® HiBiT Extracellular Detection Reagent. 
pbmc adcc reporter assay for sars-cov-2
PBMC ADCC Assay for SARS-CoV-2
 PBMC ADCC Assay for SARS-CoV-2
 PBMC ADCC Assay for SARS-CoV-2

Measurement of ADCC activity from Anti-SARS-CoV-2 S2 antibody using primary cells. Primary PBMCs were incubated with SARS-CoV-2 S CHO-K1/HiBiT target cells and anti-SARS-CoV-2 S2 antibody (Sino Biological, Cat.# 40590-D001) for 5 hours. Luminescence was measured using the Glo-Max® plate reader.

Contact us for more information on the SARS-CoV-2 PBMC ADCC Assay.

Viral Protease Assays

The SARS-CoV-2 genome encodes two proteases of therapeutic interest. 3CLpro (Main Protease or Mpro) is a chymotrypsin-like protease, and PLpro is a papain-like protease. They cleave viral polyproteins into individual proteins, and thereby play an essential role in the lifecycle of the virus. These luminescent protease assays are designed to detect viral protease activity and screen for potential  inhibitors.

Assay Design

Protease and test compound or vehicle are combined in an opaque white multi-well plate and a reaction is initiated by addition of a peptide-aminoluciferin (aLuc) substrate. The reaction is stopped, and luminescence is initiated by adding Luciferin Detection Reagent. Signal is recorded on a plate-reading luminometer. Inhibitors are identified as test compounds that reduce light output.

See this application note for a complete assay protocol.

 

SARS-CoV-2 protease assay principle

Detection of SARS-CoV-2 3CLpro inhibition with luminescent assay. A 0.2μg sample of untagged SARS-CoV-2 3CLpro (BPS Bioscience Cat.# 100823) was combined with 20μM Ac-TSTKLQ-aLuc, the 3CLpro inhibitor GC376 (AmBeed Cat.# A723661, diluted from 4mM stock DMSO solution; see Gurard-Levin et al Antiviral Research 182 (2020) 104924), 50mM HEPES (pH 7.2), 10mM DTT, and 0.1mM EDTA in a 50μl reaction volume in an opaque white 96-well plate. The reaction mixture was incubated for 60 minutes at 37°C. Reactions were then terminated by adding 50μl of Luciferin Detection Reagent (Promega Cat.# V8920/V8921). After 20 minutes at room temperature (20-25°C), luminescence was recorded on a GloMax® luminometer (Promega Cat.# GM2000).
SARS-CoV-2 3CLpro inhibition

Contact us for more information about 3CLpro and PLpro Luminescent Protease Assays.